Navigation Links
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Date:12/20/2007

leadership has earned him a reputation as one of the most experienced, innovative, and respected CMC regulatory experts in the inhalation field.

Mr. Golden began his career at GSK as a research investigator and helped to establish the Inhalation Product Development group. For almost a decade he specialized in analytical chemistry and led project teams for various inhaled products.

Prior to joining GSK, Mr. Golden was with The Upjohn Company where he developed novel laboratory and on-line analytical methods for solid and liquid dosage forms. He received his MS in Analytical Chemistry from the University of Georgia, Athens, and has presented and published extensively.

About Pearl Therapeutics, Inc.

Pearl Therapeutics is developing a pipeline of advanced respiratory products that will offer patients and their healthcare providers a choice of formulations and dosage strengths better suited to their needs. Pearl's products will afford multiple health benefits compared to current treatment options and will be available in familiar and widely used dosage forms to enhance compliance. The company has licensed advanced particle technology from Nektar Therapeutics for application in selected fields.

Founded in 2006, Pearl Therapeutics is privately held and backed by Clarus Ventures, New Leaf Ventures and 5AM Ventures.


'/>"/>
SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
5. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
6. Nile Therapeutics, Inc. Adds to Executive Management Team
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
11. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was invited ... seminar on probiotics in San Diego, CA. , The ... for health care professionals. This year’s pre-conference seminar was held ... health. Dr. Leyer spoke about the emerging topics and science ...
(Date:1/22/2015)... BRUNSWICK , Nueva Jersey , 22 de ... Award for Biomedical Research abre hoy su llamada a ... personas cuya investigación científica ha hecho, o tiene el ... la salud humana. Las nominaciones se aceptarán hasta el ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Cardium Therapeutics (NYSE Amex: CXM ) today announced ... U.S. Food and Drug Administration (FDA) seeking marketing clearance ... XL is an advanced wound care management medical ... for use by physicians in patients with topical wounds, ...
... , BENLYSTA(TM) Successful in Second Pivotal Clinical Trial ... (HGS) and GlaxoSmithKline (GSK) today announced positive results from ... trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. ... shared at the 73rd Annual Scientific meeting of the ...
... , KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ ... ) announced today the U.S. Food and Drug ... to the company,s supplemental Biologics License Application regarding ... of patients with stage III malignant melanoma after ...
Cached Biology Technology:Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 2Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 3Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds 4Promise of a New Lupus Treatment Is a Groundbreaking Achievement 2Promise of a New Lupus Treatment Is a Groundbreaking Achievement 3U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 2U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 3U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 4U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 5U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma 6
(Date:12/17/2014)... fundamentally transforming the travel experience and nowhere is this ... decade, ePassports, biometric readers, and secure document scanners have ... via eGates and Automated Passport Control (APC) Kiosks at ... across the globe. According to ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ... their offering. One major trend emerging ... advances in technology, it is important to upgrade biometric ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... storage and use of surplus blood samples taken from newborns ... explicit to non-existent, leaving many parents ill-informed about how their ... team led by a member of the Johns Hopkins Berman ... of Utah. A report on their analysis of the subject ...
... Delhi, India The Indian Government today released new tiger ... numbers have increased in the country that has half of ... tiger numbers in India at 1,706, up from 1,411 during ... an additional tiger reserve in the count, the Sundarbans, that ...
... been the leaders in the use of intra-arterial yttrium-90 ... cancer. Now, new results from a large multi-institutional study ... Y-90 than previously tried is safe, provides results when ... can be done on an outpatient basis. This study, ...
Cached Biology News:Most states unclear about storage, use of babies' blood samples, new study finds 2Most states unclear about storage, use of babies' blood samples, new study finds 3Most states unclear about storage, use of babies' blood samples, new study finds 4India releases tiger numbers as experts convene 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 2Interventional Radiology Y-90 Liver Cancer-busting Treatment: Safe, Fast, Extends Life 3
...
...
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
...
Biology Products: